Imfinzi.com


Categories

Category
Health Conditions and Concerns 73%
Biotechnology and Pharmaceuticals 9%
Health 9%
Others 9%
Explore sites in same category:
  1. ogorimii-med.net
  2. Rank 1.4M. Estimated value 1,512$
  3. ocrahope.org
  4. Rank 781.7K. Estimated value 2,760$
  5. myvision.org
  6. Rank 439.1K. Estimated value 4,932$
  7. gluten.org
  8. Rank 887.9K. Estimated value 2,424$
  9. veri.co
  10. Rank 646.5K. Estimated value 3,336$
  11. kesimpta.com
  12. Rank 1.3M. Estimated value 1,668$
  13. dr-hips.com
  14. Rank 1M. Estimated value 2,232$
  15. ito-jibika.net
  16. Rank 1.1M. Estimated value 1,968$
  17. presspogo.com
  18. Rank 663.9K. Estimated value 3,252$
  19. myeczemateam.com
  20. Rank 1.5M. Estimated value 1,392$


Keyword Suggestion

Imfinzi
Imfinzi durvalumab
Imfinzi package insert
Imfinzi immunotherapy
Imfinzi side effects
Imfinzi pi
Imfinzi hcp
Imfinzi j code
Imfinzi website
Imfinzi dosage
Imfinzi formula
Imfinzi durvalumab side effects
Imfinzi durvalumab biggest company
Imfinzi durvalumab biggest controversy
Imfinzi durvalumab indications
Imfinzi ema
Imfinzi epar
Imfinzi spc
Imfinzi fda approval history



Domain Informations

Imfinzi.com lookup results from whois.comlaude.com server:
  • Domain created: 2015-04-30T20:29:37Z
  • Domain updated: 2024-03-28T05:41:45Z
  • Domain expires: 2025-04-30T20:29:37Z 0 Years, 341 Days left
  • Website age: 9 Years, 24 Days
  • Registrar Domain ID: 1924841632_DOMAIN_COM-VRSN
  • Registrar Url: http://www.comlaude.com
  • Registrar WHOIS Server: whois.comlaude.com
  • Registrar Abuse Contact Email: [email protected]
  • Registrar Abuse Contact Phone: +442074218250
  • Name server:
    • NS-1417.AWSDNS-49.ORG
    • NS-151.AWSDNS-18.COM
    • NS-1705.AWSDNS-21.CO.UK
    • NS-724.AWSDNS-26.NET

Network
  • inetnum : 18.160.0.0 - 18.161.255.255
  • name : AMAZON-CF
  • handle : NET-18-160-0-0-1
  • status : Reallocated
  • created : 1995-01-23
  • changed : 2022-09-30
Owner
  • organization : Amazon.com, Inc.
  • handle : AMAZON-4
  • address : Array,SEATTLE,WA,98101-1244,US
Technical support
  • handle : ANO24-ARIN
  • name : Amazon EC2 Network Operations
  • phone : +1-206-555-0000
  • email : [email protected]
Abuse
  • handle : AEA8-ARIN
  • name : Amazon EC2 Abuse
  • phone : +1-206-555-0000
  • email : [email protected]
Domain Provider Number Of Domains
godaddy.com 286730
namecheap.com 101387
networksolutions.com 69118
tucows.com 52617
publicdomainregistry.com 39120
whois.godaddy.com 32793
enomdomains.com 23825
namesilo.com 21429
domains.google.com 21384
cloudflare.com 20573
gmo.jp 18110
name.com 17601
fastdomain.com 14708
register.com 13495
net.cn 12481
ionos.com 12416
ovh.com 12416
gandi.net 12305
registrar.amazon.com 12111


Host Informations

  • IP address: 18.160.41.54
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Check all domain's dns records


See Web Sites Hosted on 18.160.41.54

Fetching Web Sites Hosted


Site Inspections


Port Scanner (IP: 18.160.41.54)

 › Ftp: 21
 › Ssh: 22
 › Telnet: 23
 › Smtp: 25
 › Dns: 53
 › Http: 80
 › Pop3: 110
 › Portmapper, rpcbind: 111
 › Microsoft RPC services: 135
 › Netbios: 139
 › Imap: 143
 › Ldap: 389
 › Https: 443
 › SMB directly over IP: 445
 › Msa-outlook: 587
 › IIS, NFS, or listener RFS remote_file_sharing: 1025
 › Lotus notes: 1352
 › Sql server: 1433
 › Point-to-point tunnelling protocol: 1723
 › My sql: 3306
 › Remote desktop: 3389
 › Session Initiation Protocol (SIP): 5060
 › Virtual Network Computer display: 5900
 › X Window server: 6001
 › Webcache: 8080


Spam Check (IP: 18.160.41.54)

 › Dnsbl-1.uceprotect.net:
 › Dnsbl-2.uceprotect.net:
 › Dnsbl-3.uceprotect.net:
 › Dnsbl.dronebl.org:
 › Dnsbl.sorbs.net:
 › Spam.dnsbl.sorbs.net:
 › Bl.spamcop.net:
 › Recent.dnsbl.sorbs.net:
 › All.spamrats.com:
 › B.barracudacentral.org:
 › Bl.blocklist.de:
 › Bl.emailbasura.org:
 › Bl.mailspike.org:
 › Bl.spamcop.net:
 › Cblplus.anti-spam.org.cn:
 › Dnsbl.anticaptcha.net:
 › Ip.v4bl.org:
 › Fnrbl.fast.net:
 › Dnsrbl.swinog.ch:
 › Mail-abuse.blacklist.jippg.org:
 › Singlebl.spamgrouper.com:
 › Spam.abuse.ch:
 › Spamsources.fabel.dk:
 › Virbl.dnsbl.bit.nl:
 › Cbl.abuseat.org:
 › Dnsbl.justspam.org:
 › Zen.spamhaus.org:


Email address with imfinzi.com

Found 0 emails of this domain

Websites Listing

We found Websites Listing below when search with imfinzi.com on Search Engine

IMFINZI (durvalumab) Access & Reimbursement Guide

IMFINZI can cause immune-mediated pneumonitis, defined as requiring use of corticosteroids. Fatal cases have been reported. Monitor patients for signs and symptoms of pneumonitis and evaluate with radiographic imaging when suspected. Administer corticosteroids for Grade 2 or greater pneumonitis. Withhold IMFINZI for Grade 2 pneumonitis; permanently discontinue for …

Imfinzihcp.com

Immunotherapy for NSCLC & ES-SCLC | For HCPs | …

IMFINZI can cause severe or life-threatening infusion-related reactions. Monitor for signs and symptoms of infusion-related reactions. Interrupt, slow the rate of, or permanently discontinue IMFINZI based on the severity. See Dosing and Administration for specific details. For Grade 1 or 2 infusion-related reactions, consider using pre-medications with subsequent doses. Infusion …

Imfinzihcp.com

PRODUCT MONOGRAPH IMFINZI IMFINZI, indicated for

IMFINZI 20 mg/kg in combination with chemotherapy every 3 weeks (21 days) for 4 cycles, followed by 20 mg/kg every 4 weeks as monotherapy until weight increases to greater than 30 kg. Administer IMFINZI prior to chemotherapy when given on the same day. Please also refer to the full prescribing information for etoposide, carboplatin or cisplatin, in their respective Product …

Astrazeneca.ca

IMFINZI - pdf.hres.ca

IMFINZI (durvalumab) indicated for the treatment of patients with: Locally advanced or metastatic urothelial carcinoma who: o Have disease progression during or following platinum-containing chemotherapy o Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy has been issued marketing authorization with …

Pdf.hres.ca

To Imfinzi & Beyond… – KATHY WITH A "C"

2018-08-29  · Thursday, August 8, 2018 – Imfinzi #9. I met with Dr. H and we discussed my breathing and the anxiety issues that have come along with it. He believes the root problem is from the Imfinzi infusion messing with the scar tissue on my lung from the radiation, and the anxiety is a result of not being able to take a full breath. Based on this, he ...

Katcoonrod.com

Imfinzi plus chemotherapy significantly improved overall ...

2021-10-25  · Imfinzi plus chemotherapy was well tolerated, ... Save my name, email, and website in this browser for the next time I comment. - Advertisment - Most Popular. CDC endorses ACIP’s updated COVID-19 vaccine recommendations. December 17, 2021. Launch of UN Group of Friends on Neglected Tropical Diseases and on Support of Water . December 17, 2021. …

Lifepronow.com

Reference ID: 4223035

IMFINZI can cause immune-mediated pneumonitis, defined as requiring use of corticosteroids. Fatal cases have been reported. Monitor patients for signs and symptoms of pneumonitis. Evaluate patients with suspected pneumonitis with radiographic imaging. Administer corticosteroids, prednisone 1 to 2 mg per kg per day or equivalent for moderate (Grade 2) …

Accessdata.fda.gov

Savolitinib and IMFINZI Trial for RCC Begins - Patient Worthy

2021-11-30  · IMFINZI (durvalumab) is an intravenously administered human monoclonal antibody that works by binding to PD-L1 and preventing it from interacting with PD-1 or CD80, types of proteins. Through this process, IMFINZI stops the tumor from evading the immune system. Currently, IMFINZI is approved in varying countries for the treatment of patients with …

Patientworthy.com

First and Only Immuno-Oncology Treatment, Imfinzi ...

2018-05-08  · Imfinzi is a fully human monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses. Imfinzi has already been granted Notice of Compliance with Conditions (NOC/c) in Canada for the treatment of patients with locally …

Astrazeneca.ca

about-imfinzi-durvalumab - For HCPs

IMFINZI can cause severe or life-threatening infusion-related reactions. Monitor for signs and symptoms of infusion-related reactions. Interrupt, slow the rate of, or permanently discontinue IMFINZI based on the severity. See Dosing and Administration for specific details. For Grade 1 or 2 infusion-related reactions, consider using pre-medications with subsequent doses. Infusion …

Imfinzihcp.com

MONOGRAPHIE AVEC RENSEIGNEMENTS DESTINÉS AUX PATIENTS

Monographie d’IMFINZI®. COPYRIGHT 2017 –2021, ASTRAZENECA CANADA INC. Page 1de 59 MONOGRAPHIE AVEC RENSEIGNEMENTS DESTINÉS AUX PATIENTS IMFINZI® durvalumab pour injection Concentré en solution pour perfusion, 50 mg / mL, Perfusion intraveineuse Norme reconnue Antinéoplasique, anticorps monoclonal AstraZeneca Canada Inc.

Astrazeneca.ca

Imfinzi.be

IMFINZI is een handelsmerk van de AstraZeneca-bedrijvengroep. ©2018 AstraZeneca. Alle rechten voorbehouden. NS ID XL 0646-RD01/2019-WEB. Local code 103. Terug naar boven × ...

Imfinzi.be

Global Imfinzi Market Scope 2021 Growth Rate and Major ...

2021-12-13  · MarketsandResearch.biz provides a comprehensive research report on Global Imfinzi Market from 2021 to 2027 that provides a spot-on examination of critical drivers, and flow of the market, and potential market development. The report provides vital data and research to help shape ideal business systems and choose the expert route to improve the essential parts …

Woodlandreport.com

Imfinzi - Europa

Imfinzi . Procedural steps taken and scientific information after the authorisation . Application number Scope Opinion/ Notification. 1. issued on . Commission Decision Issued. 2 / amended on Product Information affected: 3: Summary : IB/0031/G This was an application for a group of variations. B.II.f.1.b.3 - Stability of FP - Extension of the shelf life of the finished product - After ...

Ema.europa.eu

Samsung Biologics to manufacture AstraZeneca's Covid ...

2021-12-14  · Save my name, email, and website in this browser for the next time I comment. Δ . Tel: 905-673-6625 Tel: 416-900-6669 Fax: 905-673-6636 Ad Sales Email: [email protected] Website: www.canindia ...

Canindia.com


Domains Expiration Date Updated

Site Provider Expiration Date
sexscience.org networksolutions.com 1 Year, 194 Days
elenco.com godaddy.com -2 Years, -16 Days
lessonislam.com cosmotown.com -1 Years, -124 Days
wadeca.org networksolutions.com -1 Years, -316 Days
charolais-news.com infomaniak.com -1 Years, -62 Days
totosave.com godaddy.com -1 Years, -105 Days
matirkatha.net bigrock.com 2 Years, 260 Days
primacyebooks.com namecheap.com -1 Years, -222 Days
ps94x.org whois.godaddy.com -1 Years, -68 Days
kurryzo.com godaddy.com -1 Years, -96 Days

    Browser All

    .com4.3M domains   

    .org1M domains   

    .edu40.9K domains   

    .net610.5K domains   

    .gov15.9K domains   

    .us31.1K domains   

    .ca44.9K domains   

    .de557.6K domains   

    .uk466K domains   

    .it34.6K domains   

    .au46.5K domains   

    .co34K domains   

    .biz13.8K domains   

    .info36.6K domains   

    .fr37.3K domains   

    .eu24.6K domains   

    .ru194.4K domains   

    .ph5.6K domains   

    .in54.2K domains   

    .vn18.8K domains   

    .cn40.2K domains   

    .ro19.3K domains   

    .ch11.6K domains   

    .at10.2K domains   

    Browser All